Defying Western Science, Chinese Biotech Pursues Untested Stem Cell Therapy - InformationWeek
Healthcare // Analytics
04:50 PM
Building Security for the IoT
Nov 09, 2017
In this webcast, experts discuss the most effective approaches to securing Internet-enabled system ...Read More>>

Defying Western Science, Chinese Biotech Pursues Untested Stem Cell Therapy

Although Beike Biotechnology's promising stem cell treatment is unproven, patients are paying to receive the treatment in China.

Pursuing a controversial medical procedure that shows great promise but hasn't been validated by clinical trials, a Chinese company is using stem cells to treat patients, many of them from the West, who have diseases previously thought incurable.The company, Beike Biotechnology, hosted the first China Stem Cell Technology Forum in late July.

Beike uses nonembryonic stem cells to treat a variety of ailments including heart disease and neurological disorders such as cerebral palsy, spinal cord injury, muscular dystrophy, and optic nerve hypoplasia, a primary cause of blindness in children. Its technology, which hasn't been subjected to double-blind clinical trials of the sort required by the U.S. Food and Drug Administration, uses a combination of umbilical cord cells and stem cells derived from the patient being treated. Beike is based in Shenzhen, in southeastern Guangdong Province.

Beike was founded in July 2005 with funding from Beijing University, Hong Kong University of Science and Technology, and Shenzhen City Hall. The Mandarin-language forum was attended by over 300 stem cell biologists and researchers, including several scientists based in the United States. It was described in a report in ChinaBio Today, an online newsletter that covers the biotechnology industry in China.

Unlike most countries of the West, China lacks rigorous government oversight of testing and clinical trials required before a drug or medical procedure is used on human patients.

Along with the umbilical cord cells it uses to treat patients, Beike is researching induced pluripotent stem cells (iPS cells), which are derived from cell reprogramming technologies and can be frozen and stored for later use in medical treatment. First produced in 2006 from mouse cells and in 2007 from human cells, iPS cells are considered a noncontroversial potential alternative to embryonic stem cells. A symposium on iPS cells was held in conjunction with the Stem Cell Technology Forum.

"Leading scientists in China are constantly finding ways to create more effective iPS cells," said Dr. Hu Jifan, a senior research scientist at the Palo Alto VA Health Care System in California, in a statement released by Beike. Collaboration among researchers, added Hu, "may someday create the conditions for effective clinical treatments and industrial-scale production of iPS cells."

While Beike's research on iPS cells is supported by some Western scientists, its decision to begin treating patients, who pay upward of $20,000 for a series of injections of stem cells, has raised questions among stem cell researchers.

One prospective patient is Brandon Stewart, a 7-year-old visually impaired resident of Calhan, Colo., near Colorado Springs. The boy suffers from optic nerve hypoplasia, and his parents have held a series of fundraisers to generate the $75,000 they estimate it will cost to transport him to Shenzhen for treatment. Brandon and his family plan to leave for China on Aug. 8.

Editor's note: This story was updated Aug. 6 to make clear that Beike is researching iPS cells and not using them in any treatments.

Comment  | 
Print  | 
More Insights
Newest First  |  Oldest First  |  Threaded View
User Rank: Apprentice
12/2/2015 | 8:38:40 AM
Re: Global Stem Cells Needs
Stem cells are undifferentiated human cells, which are capable of developing into any kind of cells that make up the human body. The constantly growing presence of therapeutic research activities in the stem cells field and government support are the two main factors driving the market for stem cells. 
User Rank: Strategist
12/2/2015 | 8:30:01 AM
Global Stem Cells Needs
the main factors driving the global stem cells market are the growing ubiquity of stem cells banking services, growing trend of medical tourism, greater government support, and unmet medical needs.
How Enterprises Are Attacking the IT Security Enterprise
How Enterprises Are Attacking the IT Security Enterprise
To learn more about what organizations are doing to tackle attacks and threats we surveyed a group of 300 IT and infosec professionals to find out what their biggest IT security challenges are and what they're doing to defend against today's threats. Download the report to see what they're saying.
Register for InformationWeek Newsletters
White Papers
Current Issue
2017 State of IT Report
In today's technology-driven world, "innovation" has become a basic expectation. IT leaders are tasked with making technical magic, improving customer experience, and boosting the bottom line -- yet often without any increase to the IT budget. How are organizations striking the balance between new initiatives and cost control? Download our report to learn about the biggest challenges and how savvy IT executives are overcoming them.
Twitter Feed
Sponsored Live Streaming Video
Everything You've Been Told About Mobility Is Wrong
Attend this video symposium with Sean Wisdom, Global Director of Mobility Solutions, and learn about how you can harness powerful new products to mobilize your business potential.
Flash Poll